P-493: Metabolic changes during complete blockade of raa in diabetics hypertensive patients

Abstract

The Adult Treatment Panel III of the National Cholesterol Education Program recently recommended that non-HDL cholesterol be used as a secondary target of therapy in people with triglyceride levels > 200 mg/ dl, especially those with diabetes or the metabolic Syndrome. Diabetes is associated with greatly increased CVD; many factors play a role in the accelerated atherosclerosis observed in diabetes. Non-HDL cholesterol, which reflects total cholesterol minus HDL cholesterol (i.e., apolipoprotein B– containing atherogenic lipoproteins), might be a useful marker of this combined risk.

Aim of our study is verify the effects of complete block of RAA system on dislypidemia in type 2 Diabetes hypertensive patients.

50 pts(25 male) age 70+/−12 BMI 25+/−6,Pulse pressure 65+/17 Non HDL Cholesterol 164+/−56; TG175+/− 111;Fasting glic 166+/−50 fasting Insulin 12+/−9 Hb1Ac7.1+/−2; Creat 38+/−13 Bun 85+/29 clear creat82+/−40 Microalbuminuria 27+/−70 were treated with Valsartan 80 plus Enalapril 10 mg/die for six months. We found Significant reduction [paired T-test correlated groups ( GB stat)] on : Pulse Pressure p<.0004 r=.80; fasting insulin p<.0008 r=.80;NON-HDLc p<.002 r=.70; Microalbuminuria p<.03 r=.67.

Am J Hypertens (2004) 17, 213A–213A; doi: 10.1016/j.amjhyper.2004.03.567

Diabetes, Non HDL Cholesterol, RAA System

© American Journal of Hypertension, Ltd. 2004